/
RSS Feed
 Arlene Forastiere |
 Everett Vokes |
 Michael Skinner |
 Mark Chambers |
Larynx Cancer: Concurrent Chemoradiotherapy: Best for Larynx Preservation
REFERENCE: Abstract 5517
Arlene Forastiere, Sidney Kimmel Comprehensive Cancer Center, Baltimore
In patients with larynx cancer, Arlene Forastiere of the Sidney Kimmel Comprehensive Cancer Center in Baltimore says that the best way to treat the cancer and preserve the larynx is to give radiation and chemotherapy concurrently – and not to use “induction” chemotherapy. Everett Vokes from the University of Chicago adds his comments and recommendations.
Arlene Forastiere, Sidney Kimmel Comprehensive Cancer Center, Baltimore
In patients with larynx cancer, Arlene Forastiere of the Sidney Kimmel Comprehensive Cancer Center in Baltimore says that the best way to treat the cancer and preserve the larynx is to give radiation and chemotherapy concurrently – and not to use “induction” chemotherapy. Everett Vokes from the University of Chicago adds his comments and recommendations.
ZD6474: New Treatment Avenue in Thyroid Cancer?
REFERENCE: Abstract 5533
Michael Skinner, Duke University Medical Center, Durham
Patients with hereditary metastatic medullary thyroid cancer could have a new treatment on the horizon, in the form of ZD6474, an inhibitor of the RET receptor. Michael Skinner from Duke University Medical Center in Durham had the data at ASCO.
Michael Skinner, Duke University Medical Center, Durham
Patients with hereditary metastatic medullary thyroid cancer could have a new treatment on the horizon, in the form of ZD6474, an inhibitor of the RET receptor. Michael Skinner from Duke University Medical Center in Durham had the data at ASCO.
New Remedy for Radiation Induced Oral Mucositis
REFERENCE: Abstract 5523
Mark Chambers, MD Anderson Cancer Center, Houston
Patients with oral mucositis induced by radiation for head and neck cancer may soon be able to turn to a new drug called RK-0202. Mark Chambers of the MD Anderson Cancer Center in Houston told ASCO delegates about his new study.
Mark Chambers, MD Anderson Cancer Center, Houston
Patients with oral mucositis induced by radiation for head and neck cancer may soon be able to turn to a new drug called RK-0202. Mark Chambers of the MD Anderson Cancer Center in Houston told ASCO delegates about his new study.
[audio:https://www.audiomedica.com/podcasting/asco/06.06.15_ASCO_podcast.mp3]
